Redburn Partners analyst Charles Pitman upgrades argenx (NASDAQ:ARGX) from Neutral to Buy.
Rhythm Pharma Shares Fall After Modifications To Setmelanotide Trials In Rare Diseases of Obesity
Rhythm Pharmaceuticals Inc (NASDAQ: RYTM)
Redburn Partners Upgrades argenx to Buy
Redburn Partners analyst Charles Pitman upgrades argenx (NASDAQ:ARGX) from Neutral to Buy.
Related Posts
BREAKING: Solana Ecosystem Hack Sees $580M Drained From Private Wallets…So Far
The Solana (CRYPTO: SOL) blockchain appears to be facing an ongoing exploit that has compromised users' private wallets across the ecosystem.
Maxim Group Upgrades Joint to Buy, Announces $36 Price Target
Maxim Group analyst Anthony Vendetti upgrades Joint (NASDAQ:JYNT) from Hold to Buy and announces $36 price target.
Jefferies Upgrades Dave & Buster’s Enter to Buy, Raises Price Target to $56
Jefferies analyst Andy Barish upgrades Dave & Buster's Enter (NASDAQ:PLAY) from Hold to Buy and raises the price target from $40 to $56.